RareResearch.AI
← Back to atlas

P260S

Category 3/4 — Most DruggableUncertain significanceCytoplasmic · predictedSource card
ProlineSerine at position 260 · N-terminal cytoplasmic (intrinsically disordered) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type P260 — hydrogen bond to L263
Fullscreen ↗
DynaMut2 mutant · P260S
Mutant S260 — hydrogen bond to V258 lost (3 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

3 lost1 gained4 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondS236Lost
Hydrogen bondV258Lost
Hydrogen bondS262Gained
Hydrogen bondL263L263Preserved
Polar contactS262S262Preserved
Polar contactL263L263Preserved
Van der WaalsS262S262Preserved
Van der WaalsL263Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.65kcal/mol
Destabilising — mild
AlphaMissense
0.590
likely pathogenic
AlphaFold pLDDT
59
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, single submitter
Associated conditions
Population frequency (gnomAD v4)Ultra-rare · AF 0.000068%
cDNA changec.778C>T
ClinVar accessionVCV003612029
Last evaluated2024/05/20 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — P260S Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Proline → Serine at position 260. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.590, DynaMut2 ΔΔG -0.65 kcal/mol (destabilising).


Identity

FieldValue
VariantP260S (p.Proline260Serine)
DNA changec.778C>T
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV003612029
Amino acid changeProline (P) → Serine (S)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 26059.12 — confident
DomainN-terminal cytoplasmic (intrinsically disordered)
Position contextN-terminal cytoplasmic (intrinsically disordered)
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 260 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is rigid/helix-breaking (proline — kinks backbone); the mutant is small polar (serine — hydroxyl). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.5895
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.65 (Destabilising)
Job ID178092133562
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092133562

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, single submitter
Last evaluated2024/05/20 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeP260S is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

(no conditions catalogued)


Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.65 < 2 kcal/mol (fold intact) + AlphaMissense 0.590 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.65 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.590. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • P260S_molstar_viewer.html — interactive 3D viewer (auto-highlights position 260 with ball-and-stick + neighbors within 5Å)
  • P260S_variant_card.md — this card (source of truth)
  • P260S_variant_card.html — styled printable card
  • P260S_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • P260S_wildtype_interactions.pse / P260S_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the P260S PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download P260S PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.